Epigenetic Mechanisms of Cancer

Epigenetic mechanisms refer to hereditary changes in gene expression that occur in the cell without producing changes in their genomic sequence.

Our group aims to address the part played by alterations in epigenetic mechanisms (DNA methylation and histone modification) and the genes that regulate them, as well as the role of non-coding RNA in different hematological tumors. The goal of these studies is to develop new therapies that improve the treatment and quality of life of patients with these diseases.

In the past five years, our research group has developed techniques for working both in vitro and with animal models with acute human leukemia in order to translate the results obtained in vitro to in vivo models that much more closely reflect the human disease experience.

In addition, in the last three years we have focused on analyzing the changes that occur in proteins that participate in the regulation of epigenetic mechanisms. The objective is to understand their involvement, but especially to develop new small molecules (in collaboration with the CIMA Molecular Therapies Program) that improve treatment and quality of life in patients with hematological neoplasms and cancer in general due in light of the fact that these studies show such alterations are common to most human tumors.

These studies have led to the development of a patent and a line of work that involves different types of human tumors that have a poor prognosis and lack effective therapy. This line of research is carried out in conjunction with different CIMA groups and other centers in Spain.

Our scientific projects are:

  • Development of new epigenetic therapies (small molecules) in hematological tumors (CM-272, product patented in June 2014).

  • Epigenetic regulation of the pathogenesis of multiple myeloma and other monoclonal gammopathies.

  • Identification of long non-coding RNA and its role in the diagnosis, prognosis and treatment of hematological tumors.



"Our studies have led to the development of a patent and work on human tumors with poor prognosis and with no effective therapy" , Dr. Prósper, Principal Investigator.

Contact

Contact:
Marisol Ripa
Avda. Pío XII, 53
31008 Pamplona
Spain

(+34) 948 194 700 Ext. 1010
msripa@unav.es